Kangmei Pharmaceutical Co Ltd (600518.SS)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|45||1997||Chairman of the Board, General Manager|
|44||1997||Vice Chairman of the Board, Deputy General Manager|
|42||2001||Chief Financial Officer|
|54||2008||Deputy General Manager|
|48||2017||Deputy General Manager|
- BRIEF-Kangmei Pharmaceutical to invest 47.5 mln yuan to set up genetic tech JV in Shenzhen
- BRIEF-Kangmei Pharmaceutical in deal to invest 5 bln yuan in Guizhou
- BRIEF-Kangmei Pharmaceutical's controlling shareholder issues 2017 second tranche exchangeable bonds worth 3 bln yuan
- BRIEF-Kangmei Pharmaceutical signs strategic cooperation agreement with local government
- BRIEF-Kangmei Pharmaceutical says controlling shareholder issues 2017 1st tranche non-public exchangeable bonds worth 2 bln yuan